Drugs / Intravenous immunoglobulins
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05799716 | Apr 2023 → Apr 2024 | acute transplant rejection, bacterial infectious disease | Shanghai Changzheng Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Intravenous immunoglobulins | “Intravenous immunoglobulins (IVIG) are produced by pooling together of serum immunoglobulins from multiple donors, and are known to have powerful immunomodulatory and...” NCT05799716 ↗ |
| Known as | IVIG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05799716 ↗ |
| Modality | Protein / enzyme biologic | “Intravenous immunoglobulins (IVIG) are produced by pooling together of serum immunoglobulins from multiple donors” NCT05799716 ↗ |
| Route | Intravenous | “Intravenous immunoglobulins” NCT05799716 ↗ |